NCT05003206

Brief Summary

Deep brain stimulation (DBS) is recognized as the most safe and effective neurosurgical method for the treatment of advanced Parkinson's disease. However, the mechanism of relieving motor and non-motor symptoms of Parkinson's disease has not been fully clarified, and the prognosis is significantly different. This study is based on multimodal MRI technique to clarify the mechanism of DBS in relieving motor and non-motor symptoms of Parkinson's disease, and to explore imaging indicators that can predict prognosis, so as to guide the individual and accurate treatment of Parkinson's disease (PD).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 19, 2021

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

July 1, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 12, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

August 12, 2021

Status Verified

July 1, 2021

Enrollment Period

2 years

First QC Date

July 1, 2021

Last Update Submit

August 10, 2021

Conditions

Keywords

Subthalamic nucleus deep brain stimulation

Outcome Measures

Primary Outcomes (2)

  • Clinical characteristics of patients

    Age at onset; age at surgery; disease duration; level of education; comorbidities (e.g. hypertension and diabetes mellitus); parkinsonism subtype; period of motor fluctuations; time from motor fluctuations to surgery; cigarette smoking

    1 to 2 years

  • Percentage of improvement in motor aspects (after 12 months of stimulation)

    (UPDRS III 12 months - UPDRS III baseline)/UPDRS III baseline where UPDRS III 12 months means the score of this test in "medication off , stimulation on" condition at 12 months after implant, while UPDRS III baseline means the score of this test in "medication off " condition.The clinical outcome, or degree of symptom benefit, was defined as a ≥50% improvement on a disease severity rating scale

    1 to 3 years

Secondary Outcomes (1)

  • other records:

    1 to 3 years

Study Arms (1)

PD,DBS

EXPERIMENTAL

Patients with idiopathic PD before and after DBS surgery

Other: Functional magnetic resonance imagingDevice: Deep Brain Stimulation

Interventions

Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.

PD,DBS

For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan

PD,DBS

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with Parkinson's disease
  • age\< 70 years
  • Underwent bilateral STN-DBS or not
  • Having complete medical history and clinical follow up
  • All MRI examination performed according to study protocol
  • Imaging data can be processed
  • Signed informed consent obtained from the patient or patient's legally authorized representative;

You may not qualify if:

  • Parkinson-plus syndrome or secondary parkinsonism
  • Patients with severe mental disorders such as psychosis, liver and kidney dysfunction, poor blood pressure or blood glucose control, severe depression and substance abuse, low IQ, and acute phase of severe stroke with definite limb dysfunction should also be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Interventions

Deep Brain Stimulation

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsSurgical Procedures, Operative

Study Officials

  • Xin Lou

    Chinese PLA General Hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Director of Department of Radiology

Study Record Dates

First Submitted

July 1, 2021

First Posted

August 12, 2021

Study Start

June 19, 2021

Primary Completion

July 1, 2023

Study Completion

July 1, 2025

Last Updated

August 12, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations